ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0784

Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis

Jimeng Xue1, Liling Xu1, Fanlei Hu1 and Yin Su2, 1Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing Key Laboratory for Rheumatism Mechanism and Immune Diagnosis (BZ0135), Beijing, China, Beijing, China (People's Republic), 2Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China (People's Republic)

Meeting: ACR Convergence 2020

Keywords: Monocytes/macrophages, osteoclast, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Etiology & Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The study aimed to investigate the expression and clinical significance of Tyro3TK on CD14+CD16+ and CD14+CD16– monocyte subsets and explore the effect of Tyro3TK on osteoclast formation in rheumatoid arthritis (RA).

Methods: Osteoclasts were induced by CD14+CD16+ and CD14+CD16– monocyte subsets isolated from healthy control (HC) and RA in vitro, and evaluated by tartrate-resistant acid phosphatase (TRAP) staining. Then, the expression of Tyro3TK on CD14+CD16+ and CD14+CD16– monocyte subsets were evaluated in peripheral blood of RA by flow cytometry, and the correlation between the expression of Tyro3TK on CD14+CD16+ and CD14+CD16– monocyte subsets with RA patient clinical data were analyzed. At last, the role of Tyro3TK on CD14+CD16– monocyte in RA patient osteoclastogenesis was further performed by osteoclast differentiation assay.

Results: The results revealed that CD14+CD16– monocytes were the main source of osteoclasts. The expression of Tyro3TK on CD14+CD16– monocytes was significantly upregulated in RA patients as compared with HC and osteoarthritis (OA) patients, which was positively correlated with the disease manifestations. Moreover, anti-Tyro3TK antibody could dose-dependently inhibited Gas6-mediated osteoclast differentiation in CD14+CD16– monocytes.

Conclusion: These findings indicate that elevated Tyro3TK on CD14+CD16– monocytes serves as a critical signal for osteoclast differentiation in RA, but its mechanism needs to be further studied.

The expression of Tyro3TK on CD14+CD16- monocytes is increased in RA. (A) The expression of Tyro3TK on CD14+CD16+ and CD14+CD16- monocytes in HC (n = 40), OA (n = 28), and RA patients (n = 40, **P = 0.008) were analyzed, and presented as mean fluorescence intensity (MFI). (B) The expression of Tyro3TK on CD14+CD16+ monocytes and CD14+CD16- monocytes were compared between HC, OA, and RA patients (**P = 0.008, ***P < 0.001).


Disclosure: J. Xue, None; L. Xu, None; F. Hu, None; Y. Su, None.

To cite this abstract in AMA style:

Xue J, Xu L, Hu F, Su Y. Upregulation of Tyro3TK on CD14+CD16- Monocytes Promotes Osteoclast Formation in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/upregulation-of-tyro3tk-on-cd14cd16-monocytes-promotes-osteoclast-formation-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/upregulation-of-tyro3tk-on-cd14cd16-monocytes-promotes-osteoclast-formation-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology